Ryvu Therapeutics SA · GPW:RVU

Ryvu Therapeutics SA — Investor Presentation (January 2024)

46 slides from Ryvu Therapeutics SA's investor presentation, January 2024

  1. Slide 1: Corporate Presentation: Targeted therapeutics at the forefront of oncology

    Slide 1: Corporate Presentation: Targeted therapeutics at the forefront of oncology

    CORPORATE PRESENTATION Targeted therapeutics at the forefront of oncology January 2024

  2. Slide 2: Note on the presentation and forward-looking statements

    Slide 2: Note on the presentation and forward-looking statements

    Note on the presentation and forward-looking statements This document does not constitute a public offering in the meaning of the Regulation (EU) 2017/1129 of the European Parliament and of the Council, or any other offer or invitation to acquire any Company's securities, nor the incentive to submit

  3. Slide 3: Ryvu at a glance

    Slide 3: Ryvu at a glance

    Ryvu at a glance Small Molecule Discovery Platform First-in-class clinical pipeline Novel Synthetic Lethality Targets & IO partnerships Developing small molecule therapies RVU120 MEN1703 (SEL24) which address high-value emerging targets and pathways in oncology • First-in-class, selective, • First-i

  4. Slide 4: Team with a strong track record of clinical development and shareholder value creation

    Slide 4: Team with a strong track record of clinical development and shareholder value creation

    Team with a strong track record of clinical development and shareholder value creation PAWEL PRZEWIEZLIKOWSKI, MSc, MBA KRZYSZTOF BRZOZKA, Ph.D., MBA HENDRIK NOGAI, M.D. KAMIL SITARZ, Ph.D., MBA VATNAK VAT-HO, MBA CEO and Founder CSO CMO COO CBO MIIKA AHDESMÄKI, Ph.D., MBA JAKUB JANOWSKI, MSc BARTLO

  5. Slide 5: Broad pipeline addressing emerging targets in oncology

    Slide 5: Broad pipeline addressing emerging targets in oncology

    Broad pipeline addressing emerging targets in oncology 5

  6. Slide 6: RVU120: First-in-Class CDK8/19 Inhibitor in Hematologic and Solid Tumor Malignancies

    Slide 6: RVU120: First-in-Class CDK8/19 Inhibitor in Hematologic and Solid Tumor Malignancies

    RVU120: First-in-Class CDK8/19 Inhibitor in Hematologic and Solid Tumor Malignancies

  7. Slide 7: RVU120 is a fully-owned CDK8/19 inhibitor currently in clinical development

    Slide 7: RVU120 is a fully-owned CDK8/19 inhibitor currently in clinical development

    RVU120 is a fully-owned CDK8/19 inhibitor currently in clinical development to address unmet medical needs • First-in-class • High selectivity • Easy to formulate • High potency • Low risk of DDI • Orally available RVU120 is highly selective for CDK8/19 Current RVU120 development plan may lead to th

  8. Slide 8: RVU120: opportunities across a broad range of cancers

    Slide 8: RVU120: opportunities across a broad range of cancers

    RVU120: opportunities across a broad range of cancers Blood Cancers & Disorders Solid tumors Medulloblastoma ACC AML High-risk MDS Breast Low-risk MDS Myelofibrosis (MF) Sarcoma MDS/MPN overlap syndrome NHL Diamond-Blackfan Anemia • Signs of clinical activity in AML/HR-MDS • Translational evidence i

  9. Slide 9: RVU120 for Potential Treatment of Acute Myeloid Leukemia (AML)

    Slide 9: RVU120 for Potential Treatment of Acute Myeloid Leukemia (AML)

    RVU120 for Potential Treatment of Acute Myeloid Leukemia (AML) Preclinical Evidence: AML AML • Most common, highly aggressive CD34+ AML patient-derived xenografts: type of acute leukemia in adults Complete regression Hematologic recovery • Poor outcomes in most patients1 (peripheral blood) (bone mar

  10. Slide 10: DNMT3A and NPM1 are candidates for patient selection markers in AML

    Slide 10: DNMT3A and NPM1 are candidates for patient selection markers in AML

    DNMT3A and NPM1 are candidates for patient selection markers in AML DNMT3A/NPM1 mutated AML is dependent on dysregulation of HOX genes Loss of viability with RVU120 treatment • Low nM activity on CDK8/19: RVU120 reduces the viability of AML PDCs, in particular those bearing recurrent DNMT3A and NPM1

  11. Slide 11: Combination potential with venetoclax was shown in preclinical models

    Slide 11: Combination potential with venetoclax was shown in preclinical models

    Combination potential with venetoclax was shown in preclinical models Synergistic activity was demonstrated in venetoclax sensitive Synergy is driven by regulation of MCL-1: and venetoclax resistant models: RVU120 RVU120 Venetoclax sensitive cell line MCL-1 BCL-2 BCL-XL 4000 T u m o r v o lu m e , d

  12. Slide 12: RVU120 validated preclinically as a drug candidate in myelofibrosis (MF)

    Slide 12: RVU120 validated preclinically as a drug candidate in myelofibrosis (MF)

    RVU120 validated preclinically as a drug candidate in myelofibrosis (MF) Mechanism of RVU120 activity in MF Opportunity in myelofibrosis • Growing market with many patients undiagnosed or not treated due to lack of treatment options • Long durations of therapy and unmet medical need, for example in

  13. Slide 13: Clinical results demonstrating erythroid improvement support further studies in HR-MDS and LR-MDS

    Slide 13: Clinical results demonstrating erythroid improvement support further studies in HR-MDS and LR-MDS

    Clinical results demonstrating erythroid improvement support further studies in HR-MDS and LR-MDS Growing number of patients treated with RVU120 Induction of erythroid gene expression show hematological improvement programs confirmed by RNAseq Several patients with AML and HR-MDS showed signs of imp

  14. Slide 14: RVU120: Phase I AML/MDS Study – RIVER-51

    Slide 14: RVU120: Phase I AML/MDS Study – RIVER-51

    RVU120: Phase I AML/MDS Study – RIVER-51 5 SITES IN US STUDY POPULATION: TREATMENT: Three-week cycle: Single oral dose of RVU120 every • Patients with other day for a total of 7 doses/cycle followed by relapsed/refractory AML or one week off high risk MDS • No upfront patient stratification 5 SITES

  15. Slide 15: RVU120 has a favorable safety profile at doses tested to date

    Slide 15: RVU120 has a favorable safety profile at doses tested to date

    RVU120 has a favorable safety profile at doses tested to date Antiemetic prophylaxis introduced recently improves compliance and tolerability at higher doses RVU120 (10-250 mg) Most common* Treatment Emergent RVU120 was well tolerated Adverse Events (TEAE) Any grade n of pts (%) Grade 3-5 n of pts (

  16. Slide 16: RIVER-51 Clinical Update at ASH 2023: 14 of 28 evaluable patients showed clinical benefit

    Slide 16: RIVER-51 Clinical Update at ASH 2023: 14 of 28 evaluable patients showed clinical benefit

    RIVER-51 Clinical Update at ASH 2023: 14 of 28 (50%) evaluable patients showed clinical benefit Data cut-off: Nov 10, 2023 • A total of 38 patients have been treated (28 evaluable) • Median age 72 years • 34 patients had AML and 4 had HR-MDS • Patients relapsed or were refractory to a median of 3 pr

  17. Slide 17: Patients with NPM1- and DNMT3A-mutated AML and HR-MDS achieved significant blast reductions

    Slide 17: Patients with NPM1- and DNMT3A-mutated AML and HR-MDS achieved significant blast reductions

    Patients with NPM1- and DNMT3A-mutated AML and HR-MDS achieved significant blast reductions Best BM blast % reduction After the disclosure of the chart at the ASH Annual Meeting & Exposition a further decrease of blasts from 24% to 3% (88% reduction) was reported in patient 111-001 consistent with a

  18. Slide 18: Clinical activity for RVU120 was observed in multiple populations

    Slide 18: Clinical activity for RVU120 was observed in multiple populations

    Clinical activity for RVU120 was observed in multiple populations NPM1 and DNMT3A mutations HR-MDS An NPM1 mutation was identified in 2 pts who received RVU120 • 4 pts with HR-MDS treated were failing 1-5 prior lines of treatment, including • pt 103-002: achieved a CR with skin leukemia resolution,

  19. Slide 19: RVU120 achieved target engagement levels between 50-70% at a dose of 250mg

    Slide 19: RVU120 achieved target engagement levels between 50-70% at a dose of 250mg

    RVU120 achieved target engagement levels between 50-70% at a dose of 250mg These levels are expected to result in robust antileukemic efficacy RVU120 dose - pSTAT5 inhibition RVU120 concentration – pSTAT5 inhibition • Pharmacodynamic (PD) activity of RVU120 was assessed by • Results of RVU120-induce

  20. Slide 20: RVU120: Phase I Solid Tumor Study – AMNYS-51

    Slide 20: RVU120: Phase I Solid Tumor Study – AMNYS-51

    RVU120: Phase I Solid Tumor Study – AMNYS-51 STUDY POPULATION: TREATMENT: Three week cycle: Single oral dose of RVU120 every • Patients with r/r solid other day for a total of 7 doses/cycle followed by 2 SITES IN POLAND + 3 SITES IN SPAIN tumors progressing after at one week off least one previous l

  21. Slide 21: AMNYS-51 - ESMO 2023 data release - patients treated at doses up to 400 mg

    Slide 21: AMNYS-51 - ESMO 2023 data release - patients treated at doses up to 400 mg

    AMNYS-51 - ESMO 2023 data release - 39 patients were treated at doses up to 400 mg Data cut-off: Sep 26, 2023 ▪ A total of 39 patients have been treated in 8 cohorts ▪ Patients were unselected and heavily pretreated ▪ RVU120 demonstrates a favorable safety profile. No dose limiting toxicities (DLTs)

  22. Slide 22: Data generated in RIVER-51 study support further development of RVU120

    Slide 22: Data generated in RIVER-51 study support further development of RVU120

    Data generated in RIVER-51 study support further development of RVU120, primarily in AML, HR-MDS, LR-MDS and MF RIVER-51 (Phase I) Blast reductions AML and HR-MDS RIVER-52 RIVER-81 Induction of erythropoiesis LR-MDS REMARK Transfusion independence MF POTAMI-61 Improvement of bone marrow architecture

  23. Slide 23: RIVER-52: Phase II study with RVU120 as a single agent

    Slide 23: RIVER-52: Phase II study with RVU120 as a single agent

    RIVER-52: Phase II study with RVU120 as a single agent Based on convincing translational rationale and clinical data, patients will be selected based on the disease features and genetic background STUDY DESIGN • Primary endpoints: o Rate of CR, CRh, CRi, with and without MRD, and DoR • Secondary end

  24. Slide 24: RIVER-81: Phase II study testing RVU120 in combination with venetoclax

    Slide 24: RIVER-81: Phase II study testing RVU120 in combination with venetoclax

    RIVER-81: Phase II study testing RVU120 in combination with venetoclax STUDY DESIGN ▪ Primary endpoints: RVU120 ▪ Rate of CR, CRh, CRi, with and without MRD, and DoR ▪ Secondary endpoints: Transfusion independence, PFS, RFS, OS venetoclax ▪ For Stage 2: including PRO and HRQoL change from baseline ▪

  25. Slide 25: REMARK: RVU120 in LR-MDS – IIT conducted by Prof. Uwe Platzbecker and the EMSCO network

    Slide 25: REMARK: RVU120 in LR-MDS – IIT conducted by Prof. Uwe Platzbecker and the EMSCO network

    REMARK: RVU120 in LR-MDS – IIT conducted by Prof. Uwe Platzbecker and the EMSCO network ▪ Population: PHASE II ▪ Relapsed/refractory low-risk MDS for the treatment STUDY DESIGN of anemia in patients failing available options Exploratory ▪ Opportunity for the first line (1L) setting RVU120 as a singl

  26. Slide 26: Clinical Development of RVU120 focuses on hematologic malignancies

    Slide 26: Clinical Development of RVU120 focuses on hematologic malignancies

    Clinical Development of RVU120 focuses on hematologic malignancies, while translational research explores additional opportunities 2024 2025 2026 2027 2028 I II III IV I II III IV I II III IV I II III IV I II III IV Planned Ph II studies in hematologic malignancies decision point for prioritization

  27. Slide 27: Phase II clinical development of RVU120 with a global footprint

    Slide 27: Phase II clinical development of RVU120 with a global footprint

    Phase II clinical development of RVU120 with a global footprint Global site locations and patient population Global CROs and clinical vendors Regulatory authorities worldwide Planned locations for RVU120 Ph II studies: Part 1: exploratory data Part 2: expansion 4 10+ 170+ 270+ 30+ 50+ Number of Ph I

  28. Slide 28: RVU120 market potential in hematological malignancies

    Slide 28: RVU120 market potential in hematological malignancies

    RVU120 market potential in hematological malignancies AML (ACUTE MYELOID LEUKEMIA) MDS (MYELODYSPLASTIC SYNDROME) MF (MYELOFIBROSIS) ▪ The most common, highly ▪ Disease leading to bone marrow ▪ MF is a bone marrow disease aggressive type of acute leukemia damage, classified as cancer characterized b

  29. Slide 29: MEN1703 (SEL24): First-in-Class PIM/FLT3 Inhibitor

    Slide 29: MEN1703 (SEL24): First-in-Class PIM/FLT3 Inhibitor

    MEN1703 (SEL24): First-in-Class PIM/FLT3 Inhibitor

  30. Slide 30: MEN1703 (SEL24) – Summary

    Slide 30: MEN1703 (SEL24) – Summary

    MEN1703 (SEL24) – Summary Licensed to Menarini Group, currently in Phase II Future directions – 2023+ PARTNERSHIP AGREEMENT PROVEN SAFETY AND WITH MENARINI GROUP CLINICAL ACTIVITY DLBCL (2017) • Development to continue with the initiation of a new Phase II study in relapsed/refractory diffuse large

  31. Slide 31: Unmet medical need and high commercial potential for MEN1703 in DLBCL

    Slide 31: Unmet medical need and high commercial potential for MEN1703 in DLBCL

    Unmet medical need and high commercial potential for MEN1703 in DLBCL DLBCL (Diffuse Large B-Cell Lymphoma) COMMERCIAL POTENTIAL AND UNMET NEED • Strong unmet medical need: estimated 23k incident DLBCL cases in North • Non Hodgkin’s lymphomas (NHL) are a heterogeneous group of America in 2027 and 37

  32. Slide 32: Initiating Phase II in DLBCL

    Slide 32: Initiating Phase II in DLBCL

    Initiating Phase II in DLBCL MEN1703 • First-in-class dual PIM/FLT3 inhibitor with a unique mechanism of action PROFILE • Differentiated activity in cellular models compared to selective PIM inhibitors (broader activity profile) • H1 2017- H1 2021 Phase I dose escalation and cohort expansion in R/R

  33. Slide 33: Small Molecule Platform with Focus on Synthetic Lethality

    Slide 33: Small Molecule Platform with Focus on Synthetic Lethality

    Small Molecule Platform with Focus on Synthetic Lethality

  34. Slide 34: Integrated Discovery Engine at Ryvu

    Slide 34: Integrated Discovery Engine at Ryvu

    Integrated Discovery Engine at Ryvu TARGET IDENTIFICATION AND VALIDATION DRUG DISCOVERY RESEARCH PIPELINE ✓ Discovery of novel synthetic lethal target ✓ Integrated, multidisciplinary processes: ✓ Broad portfolio of synthetic lethal and pairs and actionable oncogenic drivers rapid lead identification

  35. Slide 35: Ryvu's Target Discovery Platform is focused on identification of novel synthetic lethal pairs

    Slide 35: Ryvu's Target Discovery Platform is focused on identification of novel synthetic lethal pairs

    Ryvu’s Target Discovery Platform is focused on identification of novel synthetic lethal pairs and oncogenic drivers INPUT DATA TARGET DISCOVERY PLATFORM PLATFORM OUTPUT CRISPR / shRNA Screens Novel Synthetic Lethalities Novel and Proprietary SL Targets Published Data Sets Novel oncogenic drivers 35

  36. Slide 36: Ryvu experimental target discovery platform – three approaches

    Slide 36: Ryvu experimental target discovery platform – three approaches

    Ryvu experimental target discovery platform – three approaches Experimental CRISPR-based target discovery platforms with the use of: Isogenic cell line pair Isogenic primary cells Patient-derived material Normal conditions Stress conditions MUT1 MUT2 MUT3 MUT4 CRISPR screens Cellular stress in tumor

  37. Slide 37: PRMT5 MTA-cooperative inhibitors

    Slide 37: PRMT5 MTA-cooperative inhibitors

    PRMT5 MTA-cooperative inhibitors RYVU HAS SL PRMT5 INHIBITORS WITH THE BEST-IN-CLASS POTENTIAL PRMT5 SL INHIBITOR PROGRAM IN RYVU Ryvu PRMT5 inhibitors demonstrate high potency and MTA-cooperativity in vitro coupled with favorable ADME profile. PRMT5 MTA-cooperative inhibitors KEY RATIONALE exert sy

  38. Slide 38: Small molecule inhibitors of WRN

    Slide 38: Small molecule inhibitors of WRN

    Small molecule inhibitors of WRN WRN INHIBITORS OF ATPase ACTIVITY SELECTIVELY TARGETING TUMORS WRN INHIBITOR PROGRAM AT RYVU WITH MICROSATELLITE INSTABILITY Synthetic lethality of WRN 1 KEY RATIONALE Helicase function validated with microsatellite instability (MSI-high) in vitro as critical require

  39. Slide 39: BioNTech and Ryvu: Global Collaboration to Develop and Commercialize Immune Modulation Small Molecule Candidates

    Slide 39: BioNTech and Ryvu: Global Collaboration to Develop and Commercialize Immune Modulation Small Molecule Candidates

    BioNTech and Ryvu: Global Collaboration to Develop and Commercialize Immune Modulation Small Molecule Candidates Largest-ever Ryvu deal November 2022 • Multi-target discovery collaboration on small molecule programs in immune modulation • STING agonist license as a monotherapy and in combinations Pa

  40. Slide 40: Exelixis and Ryvu: Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies

    Slide 40: Exelixis and Ryvu: Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies

    Exelixis and Ryvu: Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies July 2022 • Building STING-based antibody drug conjugates (ADCs) • Leveraging Ryvu’s STING agonist portfolio and Exelixis’s ADC technology Partnership Key Financial Terms • Exclusive license

  41. Slide 41: Corporate Progress

    Slide 41: Corporate Progress

    Corporate Progress

  42. Slide 42: Full-Year Financial Results: Q3YTD 2023

    Slide 42: Full-Year Financial Results: Q3YTD 2023

    Full-Year Financial Results: Q3YTD 2023 Q3YTD Q3YTD $ million 2022* 2022* 2023* Cash position # of employees Revenues, incl.: 15.8 8.0 11.9 November 24, 2023 Partnering 8.7 3.2 8.4 Grants 6.6 4.4 3.3 $64.5M Total Costs**, incl.: 26.4 19.2 27.4 Clinical Pipeline 6.4 5.0 9.7 Available EIB Venture Debt

  43. Slide 43: EUR 22m venture debt obtained from the European Investment Bank

    Slide 43: EUR 22m venture debt obtained from the European Investment Bank

    EUR 22m venture debt obtained from the European Investment Bank Long-term financing for innovative growth companies: Instrument structure adapted to the business model Long-term financing repaid through bullet repayment, and remuneration independent of interest rates, partially secured by the Compan

  44. Slide 44: Business Pipeline: 2024 key goals and financing

    Slide 44: Business Pipeline: 2024 key goals and financing

    Ryvu’s Vision: From 2026, Ryvu will improve the lives of cancer patients worldwide 2024 KEY GOALS AND FINANCING ▪ Research funding from existing R&D collaborations ▪ RVU120 broad development ▪ Milestones from existing R&D collaborations ▪ New grant funding (including potential fast-to-market strateg

  45. Slide 45: Ryvu Equity Summary

    Slide 45: Ryvu Equity Summary

    Ryvu Equity Summary Top Holders3 IPO on WSE Nov 2014 1 Paweł Przewięźlikowski 18% Corporate Split: Selvita and Ryvu Oct 2019 2 Allianz OFE 9.2% Ticker: WSE RVU 3 BioNTech SE 8.3% 4 Allianz TFI 8.3% 52-Week Range1 PLN 51.70 – 72.40 5 Nationale-Nederlanden OFE 8.2% Average Daily Volume (YTD) 1 15,099

  46. Slide 46: Contact Data

    Slide 46: Contact Data

    CONTACT DATA: Ryvu Therapeutics S.A. www.ryvu.com ryvu@ryvu.com 46

Source: Internet Archive copy of ryvu.com

More decks from Ryvu Therapeutics SA

All 21 Ryvu Therapeutics SA decks